<?xml version='1.0' encoding='utf-8'?>
<document id="11602524"><sentence text="Testosterone, 7-benzyloxyquinoline, and 7-benzyloxy-4-trifluoromethyl-coumarin bind to different domains within the active site of cytochrome P450 3A4."><entity charOffset="0-12" id="DDI-PubMed.11602524.s1.e0" text="Testosterone" /><entity charOffset="14-34" id="DDI-PubMed.11602524.s1.e1" text="7-benzyloxyquinoline" /><entity charOffset="40-78" id="DDI-PubMed.11602524.s1.e2" text="7-benzyloxy-4-trifluoromethyl-coumarin" /><pair ddi="false" e1="DDI-PubMed.11602524.s1.e0" e2="DDI-PubMed.11602524.s1.e0" /><pair ddi="false" e1="DDI-PubMed.11602524.s1.e0" e2="DDI-PubMed.11602524.s1.e1" /><pair ddi="false" e1="DDI-PubMed.11602524.s1.e0" e2="DDI-PubMed.11602524.s1.e2" /><pair ddi="false" e1="DDI-PubMed.11602524.s1.e1" e2="DDI-PubMed.11602524.s1.e1" /><pair ddi="false" e1="DDI-PubMed.11602524.s1.e1" e2="DDI-PubMed.11602524.s1.e2" /></sentence><sentence text="Testosterone, 7-benzyloxyquinoline, and 7-benzyloxy-4-trifluoromethyl-coumarin, marker substrates for cytochrome P450 3A4 are commonly used within the pharmaceutical industry to screen new chemical entities as inhibitors of CYP3A4 in a high-throughput manner to predict the potential for drug-drug interactions"><entity charOffset="0-12" id="DDI-PubMed.11602524.s2.e0" text="Testosterone" /><entity charOffset="14-34" id="DDI-PubMed.11602524.s2.e1" text="7-benzyloxyquinoline" /><entity charOffset="40-78" id="DDI-PubMed.11602524.s2.e2" text="7-benzyloxy-4-trifluoromethyl-coumarin" /><pair ddi="false" e1="DDI-PubMed.11602524.s2.e0" e2="DDI-PubMed.11602524.s2.e0" /><pair ddi="false" e1="DDI-PubMed.11602524.s2.e0" e2="DDI-PubMed.11602524.s2.e1" /><pair ddi="false" e1="DDI-PubMed.11602524.s2.e0" e2="DDI-PubMed.11602524.s2.e2" /><pair ddi="false" e1="DDI-PubMed.11602524.s2.e1" e2="DDI-PubMed.11602524.s2.e1" /><pair ddi="false" e1="DDI-PubMed.11602524.s2.e1" e2="DDI-PubMed.11602524.s2.e2" /></sentence><sentence text=" However, it has been observed that inhibition data obtained with a given CYP3A4 probe substrate may not correlate well with results from a different probe" /><sentence text=" As a consequence, the choice of the probe compound becomes an important consideration in such screens" /><sentence text=" In the present study, kinetic interactions between either two of the above three substrates were evaluated, and three-dimensional nonlinear regression analysis was performed to understand the kinetic mechanisms of drug interaction" /><sentence text=" Our results demonstrate that the kinetic interaction between each pair of substrates does not appear to be competitive and that the interactions are characterized by an unchanged or a decrease in both apparent K(m) (a = 0" /><sentence text="21-0" /><sentence text="72, a change of K(m) in the absence of the effector) and V(max) (alpha and beta = 0" /><sentence text="09-0" /><sentence text="75, changes of V(max) in the absence of the effector)" /><sentence text=" These data suggest that 1) the three substrates bind to different domains; 2) at least two substrates can coexist in the active site of CYP3A4; and 3) the two bound substrates interact kinetically with each other (e" /><sentence text="g" /><sentence text=", through steric hindrance), thereby leading to a change in both apparent kinetic parameters and partial inhibition" /><sentence text=" Selection of multiple substrates, which are shown not to be competitive, is necessary to accurately predict CYP3A4 inhibition and the potential for drug-drug interaction" /><sentence text="" /></document>